BioPharma Dive February 26, 2025
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.
Eli Lilly will invest tens of billions more dollars in U.S. drug manufacturing in a significant enlargement of plans the Indianapolis company had already described as historic.
Lilly, which makes the popular obesity medicine Zepbound, previously pledged to spend $23 billion on constructing and refurbishing factories in the U.S. to churn out the company’s new pills and injections. On Tuesday, the company more than doubled that target. Including commitments made since 2020, it expects to pour over $50 billion into U.S. capital expenditures.
According to Lilly, the planned spending is the largest pharmaceutical investment in domestic manufacturing...
Today's Sponsors
Today's Sponsor